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Alterations in brain iron homeostasis are a hall-
mark of neurodegenerative diseases (Berg and 
Youdim, 2006). Localized iron overload is asso-
ciated with both Alzheimer’s and Parkinson’s 
disease (Altamura and Muckenthaler, 2009), and 
with a group of genetic disorders termed neu-
rodegeneration with brain iron accumulation 
(Hayflick, 2006). Besides, brain iron deficiency 
is related to neurodegenerative processes like 
restless leg syndrome (RLS; Salas et al., 2010) 
and epilepsy (Ozaydin et al., 2012). Several 
studies analyzed cerebral spinal fluid or brain 
samples for iron content and iron-containing 
proteins or by brain imaging (Clardy et al., 2006; 
Connor et al., 2011; Allen et al., 2001; Allen, 
2004) and showed that RLS is hallmarked by 
low cerebral iron levels that particularly affect 
the dopamine-producing cells of the substantia 
nigra (Connor et al., 2011). In contrast, the di-
rect link between iron deficiency and epilepsy 
still remains controversial (Idro et al., 2010; 
Sherjil et al., 2010).
The iron storage protein ferritin plays a 
central role in maintaining systemic and cellular 
iron levels. It sequesters the metal inside of its 
internal cavity to satisfy cellular iron demands 
and to prevent toxicities arising from Fenton-
like reactions (Arosio and Levi, 2010). In verte-
brates, three different genes (FTL, FTH, and 
FTMT) code for ferritin proteins with a highly 
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The ubiquitously expressed iron storage protein ferritin plays a central role in maintaining 
cellular iron homeostasis. Cytosolic ferritins are composed of heavy (H) and light (L) sub-
units that co-assemble into a hollow spherical shell with an internal cavity where iron is 
stored. The ferroxidase activity of the ferritin H chain is critical to store iron in its Fe3+ 
oxidation state, while the L chain shows iron nucleation properties. We describe a unique 
case of a 23-yr-old female patient affected by a homozygous loss of function mutation in 
the L-ferritin gene, idiopathic generalized seizures, and atypical restless leg syndrome (RLS). 
We show that L chain ferritin is undetectable in primary fibroblasts from the patient, and 
thus ferritin consists only of H chains. Increased iron incorporation into the FtH homopoly-
mer leads to reduced cellular iron availability, diminished levels of cytosolic catalase, SOD1 
protein levels, enhanced ROS production and higher levels of oxidized proteins. Importantly, 
key phenotypic features observed in fibroblasts are also mirrored in reprogrammed neurons 
from the patient’s fibroblasts. Our results demonstrate for the first time the pathophysi-
ological consequences of L-ferritin deficiency in a human and help to define the concept 
for a new disease entity hallmarked by idiopathic generalized seizure and atypical RLS.
© 2013 Cozzi et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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FtL peptide (Levi et al., 2005; Cozzi et al., 2010). The affected 
patients show movement disorders and abundant spherical 
inclusions that contain ferritin and iron in the brain and other 
organs (Burn and Chinnery, 2006). Furthermore, patients 
carrying the heterozygous missense mutation Thr30Ile and 
the recently identified Gln26Ile and Ala27Val show hyperfer-
ritinemia and an increased amount of glycosylated ferritin 
(Kannengiesser et al., 2009; Thurlow et al., 2012), whereas 
haploinsufficiency occurs in a subject with an altered start 
codon in one allele, which caused abnormally low levels of 
FtL in serum and tissues (Cremonesi et al., 2004).
Here, we describe the first patient with a complete loss of 
FtL function caused by a homozygous mutation (310G>T), 
located in exon 3 of the FtL gene, which generates a stop 
codon at aa 104. The patient was affected by idiopathic gen-
eralized seizures during infancy and atypical RLS, as defined 
by polysomnography in the absence of periodic limb move-
ments. Molecular analyses reveal that the truncated peptide is 
unable to assemble with the H subunit to form the full ferri-
tin cage. Fibroblasts derived from the patient that exclusively 
express a H chain homopolymer are hallmarked by alterations 
of cellular iron homeostasis and oxidative stress; findings mir-
rored in induced neurons (iNs) from the patient.
RESULTS
Detection of a homozygous STOP codon at amino  
acid 104 of the FTL gene in a patient
In our patient with undetectable serum ferritin levels, idio-
pathic generalized seizures, and atypical RLS, we screened 
all exons encoding the FTL gene for neuroferritinopathy- 
associated mutations and detected a G>T nucleotide substi-
tution (G310T) in exon 3 (Fig. 1 A). This base substitution 
generates a stop codon in the corresponding amino acid 104 
(E104X; Fig. 1 B, top). The 3D structure of ferritin containing 
L subunits (Ford et al., 1984) predicts that amino acid residue 
E104 is located in the middle of a-helix C (Fig. 1 B, bottom), 
where it engages a salt bridge with aa K58. This salt bridge 
was described to be critical for the stability of the full molecule 
(Santambrogio et al., 1992). Mutational studies on ferritin 
peptides (Levi et al., 1989, 1994; Yewdall et al., 1990; Luscieti 
et al., 2010) suggest that a stop codon at this position produces a 
truncated peptide unable to fold into a full ferritin cage.
FtL expression is not detectable in fibroblasts  
from a patient with the FtL G 310>T variant
To analyze the expression of the FtL variant in our patient, we 
derived fibroblasts (termed E104X) from a patient’s skin bi-
opsy and from three healthy control subjects (termed CTR1, 
CTR2, and CTR3). To determine ferritin subunit compo-
sition in E104X and control fibroblasts, we metabolically 
labeled the cells with 50 µCi [35S]methionine for 18 h and 
prepared cellular homogenates that were sequentially immu-
noprecipitated, first with anti–ferritin L chain (aFtL) and then 
with anti–H chain (aFtH) antibodies (Fig. 1 C). Although FtL 
was detectable in control fibroblasts, the predicted 11-kD 
L chain variant could not be detected in E104X cells. In addition, 
conserved 3D structure (Lawson et al., 1991; Langlois d’Estaintot 
et al., 2004; Luscieti et al., 2010). FTL and FTH code for cyto-
solic ferritins (Arosio and Levi, 2010) that co-assemble into a 
heteropolymer to form a hollow spherical shell with an inter-
nal cavity where iron is stored (Zhao et al., 2003). Different 
tissues express different ratios of the H- and L-ferritin sub-
units (FtH and FtL; Arosio and Levi, 2010). The FTMT gene 
codes for a mitochondrial-targeted ferritin, which assembles 
into a homopolymer of 24 identical subunits (Levi et al., 2001). 
Both, the H and Mt ferritin subunits exert ferroxidase activity 
(Levi et al., 1988; Levi and Arosio, 2004), whereas the L sub-
unit shows an active nucleation center on the cavity surface, 
which favors iron storage (Levi et al., 1992; Levi et al., 1994).
Expression of the FTH and FTL genes is regulated in re-
sponse to the intracellular labile iron pool (LIP) by iron regu-
latory proteins 1 and 2 (IRPs; Hentze et al., 2010). IRPs bind 
the iron responsive element (IRE), a RNA stem loop struc-
ture located within the 5 untranslated region of FtL and FtH 
mRNAs. The IRP–IRE complex is formed under iron- 
deficient conditions and prevents mRNA translation (Recalcati 
et al., 2010).
The critical importance of cytosolic ferritin in maintain-
ing iron homeostasis is highlighted by the genetic ablation of 
the ferritin genes in animal models (Ferreira et al., 2000, 2001; 
Thompson et al., 2003; Missirlis et al., 2007; Darshan et al., 
2009). In Drosophila melanogaster both FtH and FtL are essen-
tial for embryonic development (Missirlis et al., 2007). Simi-
larly, homozygous null mice for FtH die in utero, indicating 
that the ferroxidase activity of the H subunit is essential dur-
ing mammalian embryonic development (Ferreira et al., 2000). 
Heterozygous ferritin-H +/ mice show mild iron deficiency 
(Ferreira et al., 2001) and increased indices of oxidative stress 
in brain tissues (Thompson et al., 2003). Conditional knock-
out of the FTH gene in the liver induced hepatic damage 
and rapid cell death in mouse embryonic fibroblasts (Darshan 
et al., 2009).
In contrast, a deletion of the FTL gene in vertebrates has 
not been described. However, several pathogenic human mu-
tations were reported in the FTL gene (Levi et al., 2005). 
These cause at least two types of dominant disorders: heredi-
tary hyperferritinemia with cataract (HHCS; OMIM 600886; 
Beaumont et al., 1995) or (neuro)ferritinopathy (OMIM 606159; 
Curtis et al., 2001; Vidal et al., 2004), depending on the loca-
tion of the mutation within the FTL gene. In subjects af-
fected by HHCS, mutations most commonly occur within 
the IRE stem loop of the FtL mRNA (Millonig et al., 2010). 
These mutations reduce the affinity for IRP binding and, as 
a result, these patients produce 2–10 fold more FtL in tissues 
and serum with no associated abnormalities in iron homeostasis 
(Millonig et al., 2010). Excess ferritin aggregates in micro crys-
tals in the lens induce nuclear and bilateral cataract (Brooks 
et al., 2002). Neuroferritinopathy, a rare neurodegenerative 
disease with autosomal and dominant transmission (Curtis 
et al., 2001), is caused by single or multiple nucleotides inser-
tions in exon 4 of the FTL gene. These mutations cause frame-
shifts and large alterations of the C-terminal sequence of the 
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chain expression was not impaired by the lack of L chain ex-
pression in E104X fibroblasts (Fig.1 D).
H homopolymer ferritin formation induces iron deficiency
To analyze ferritin properties in E104X fibroblasts, we treated 
cells with 2 µCi 55Fe-ammonium citrate (FAC) for 18 h. Total 
cellular 55Fe levels (Fig. 2 A) and incorporation of iron into 
ferritin (Fig. 2 B) were increased by approximately twofold in 
E104X fibroblasts compared with control cells, as detected by 
counting radiolabeled iron and by autoradiography of cellular 
extract electrophoretic analysis, respectively. Increased iron 
incorporation into ferritin may cause intracellular iron starva-
tion that can be monitored by the level of the LIP. Thus, we 
next analyzed the LIP by a fluorescent-permeable metal sen-
sor, calcein-AM (Picard et al., 1998). Fibroblasts were incu-
bated with 0.250 µM calcein-AM for 15 min at 37°C, and an 
increase in fluorescence emission at 535 nm was monitored 
after addition of the permeable chelator deferiprone (Fig. 2 C). 
The basal LIP level of E104X cells was approximately four-
fold lower compared with the controls. To verify if the absence 
of L chain expression was the cause for the LIP reduction, we 
FtL was not detectable in E104X fibroblasts by application of 
a specific ELISA, whereas FtH levels were comparable in all 
control cells (Table 1), suggesting a similar capacity for iron 
incorporation. Importantly, the amount of FtL mRNA ex-
pression was similar in E104X and control cells, and FtH 
Figure 1. FtL expression is undetectable in fibroblasts from a patient with the FtL G 310>T variant. (A, top) The pherogram shows the homo-
zygous G>T exchange at nt 310 (counted from the first nucleotide of the starting codon) in exon 3 of the patient’s ferritin gene and (bottom) the corre-
sponding heterozygous mutation in parent’s DNA is shown. (B) Sequence alignment of the partial exon 3 of the human FtL (Lwt) and FtL variant (G310T), 
as well as the 3D structure scheme of L ferritin subunits. The arrow indicates the mutated position. (C) [35S]methionine–labeled ferritin. Fibroblasts derived 
from the patient (E104X) and a control proband (CTR1) were metabolically labeled with 50 µCi/ml [35S]methionine for 18 h and lysed, and then 4 × 106 cpm  
of the homogenates were precipitated with saturating amounts of anti–FtL antibody (aFtL). The soluble fraction was precipitated again with an anti-FtH 
antibody (aFtH) and analyzed on a 12% SDS-PAGE, which was subjected to autoradiography. One of two representative experiments. (D) Ferritin mRNA 
levels were determined by quantitative real-time PCR for FtL and FtH and normalized to mRNA expression of GAPDH. Data are the mean ± SD values of 
three independent experiments.
Table 1. Ferritin level
FtL  
(ng/mg prot.)
FtH  
(ng/mg prot.)
CTR1 11 ± 1.5 162 ± 12.7
CTR2 19 ± 7.0 116 ± 17.0
CTR3 10 ± 3.0 133 ± 23.0
E104X Undetected 148 ± 23.0
E104X-Lwt 14 ± 1.0 135 ± 33.0
L (FtL) and H (FtH) chain ferritin was analyzed in cell extracts of fibroblasts from 
three different healthy control probands, our patient (E104X), and patient 
fibroblasts with forced FtL expression (E104X-Lwt) by an ELISA. The results are 
shown as nanograms/milligram of ferritin of total soluble proteins. The values are 
the means and SD of three independent experiments.
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reduced cellular iron availability, which can be compensated 
for by forced FtL expression.
H homopolymer ferritin formation triggers  
oxidative stress and cellular damage
Free iron promotes the formation of free radicals, and thus we 
hypothesized that reduced iron levels detected in fibroblasts 
may improve resistance to oxidative stress. To test this, the via-
bility of fibroblasts was analyzed by the MTT assay after treat-
ment with 0.6 mM H2O2 for 2 h. Unexpectedly, the oxidative 
insult decreased the number of viable E104X fibroblasts by 
25% compared with 10% in control cells (Fig. 3 A). To fur-
ther investigate the increased sensitivity to oxidative insult, 
fibroblasts were incubated with increasing concentrations of 
H2O2 for 30 min and ROS levels were determined by dihy-
drorhodamine 123 (DHR-123). Interestingly, we observe a 
overexpressed the wild-type L chain ferritin in E104X fibro-
blasts (named E104X-Lwt) by transduction with a lentiviral 
vector (Lv-GFP-FtL; Cozzi et al., 2010). Transduction effi-
ciency was visualized by monitoring GFP cells and was shown 
to be up to 60%. 10 d later, the expression of FtH and FtL was 
assayed by ELISA (Table 1). As expected, ferritin levels were 
now similar to that of the controls, and the LIP recovered up 
to 75% of the controls (Fig. 2 C). To further assay cellular 
iron availability, we analyzed the IRP binding activity by elec-
trophoretic mobility shift assay (EMSA) and transferrin re-
ceptor 1 (TfR1) expression by immunoblotting. Consistent 
with reduced iron availability in E104X fibroblasts, both IRP 
binding activity (Fig. 2 D) and TfR1 expression (Fig. 2 E) 
were increased by 1.5-fold compared with control cells. 
Collectively, these data suggest that a lack of FtL results in an 
increased iron binding capacity of the FtH homopolymer and 
Figure 2. H homopolymer ferritin formation induces iron deficiency. Iron incorporation into cells and ferritin was analyzed in 2 × 105 cells incu-
bated for 18 h in medium supplemented with 2 µCi/ml 55Fe-FAC. (A) Cellular 55Fe incorporation. Radioactivity of total soluble homogenates expressed as 
cpm/mg of total proteins. *, P ≤ 0.001. (B) Ferritin 55Fe incorporation. Samples of soluble cell homogenates containing 10 µg of protein were separated on 
a 7% nondenaturing PAGE (the arrow indicates ferritin mobility), exposed to autoradiography, and evaluated by densitometry. The results are expressed 
as relative value to the mean of the controls of three independent experiments. *, P ≤ 0.001. (C) LIP. The assay was performed with 4 × 104 cells; they were 
incubated with 0.250 µM calcein-AM for 15 min at 37°C, and then with cells. The increase in fluorescence emission at 535 nm was monitored after addi-
tion of the permeable iron chelator deferiprone (0.2 mM). °, P ≤ 0.002; *, P ≤ 0.001. (D) IRP activity. 2 µg of total soluble protein extracts were incubated 
with a 32P-labeled IRE-ferritin probe in the absence or presence of 2% 2-mercaptoethanol, and RNA–protein complexes were separated on 6% nondena-
turing PAGE and exposed to autoradiography. Mobility shifted bands were quantified. *, P ≤ 0.05. (E) TfR1 expression. 20 µg of soluble cell homogenates 
were separated on a 12% SDS-PAGE, blotted, and incubated with an anti–human TfR1 antibody. Quantification was performed by densitometry. *, P ≤ 
0.05. Results in C–E show the mean of three independent experiments.
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Figure 3. H homopolymer ferritin induces oxidative damage and shows a reduced half-life. (A) Cellular vitality. Cells (104) were incubated for 2 h with  
0.6 mM H2O2 in serum-free medium and cellular vitality was measured by MTT assay. Data are the mean of two independent experiments in octoplicate. *, P ≤ 0.05.  
(B) ROS levels. Cells (104) were incubated for 15 min with 30 µM of dihydrorhodamine, washed, and treated with different amounts of H2O2 for 30 min. Fluorescence 
was measured at 535 nm. Results are the mean of two independent experiments in octoplicate. *, P ≤ 0.05. (C) Oxidized proteins. The levels of carbonylated proteins 
were analyzed by oxyblot (see Materials and methods). (D) GSSG. 104 cells were treated or not with 5 mM of TCEP (tris(2-carboxyethyl)phosphine) for 20 min at room 
temperature and analyzed according to the manufacturer’s instructions. Oxidized glutathione is shown as relative value of the total. Shown is a representative experi-
ment, in triplicate, of two independent experiments. *, P ≤ 0.009. Catalase and SOD1 expression. 25 µg of total soluble proteins were separated on a 12% SDS-PAGE, 
blotted, and incubated with an anti-catalase (E) or anti-SOD1 (F) antibodies. Quantification of bands was performed by densitometry. The results show the mean of 
three experiments. *, P ≤ 0.001. (G) SOD activities. Fibroblast cell extracts (15 µg) of controls (CTR) and patient (E104X) were loaded on a 12% nondenaturing PAGE and 
analyzed for SOD activities by nitroblue tetrazolium staining. SOD2 and SOD1 indicate the activity of the mitochondrial MnSOD2 and cytosolic SOD1 enzymes, respec-
tively. The two extracts E104X (1) and (2) indicate the extreme points of the variability range. One representative of four independent experiments is shown. (H) Ferritin 
turnover. L-variant and control cells were metabolically labeled for 18 h with 50 µCi/ml 35S-methionine in methionine-free medium. After washing, the cells were 
maintained in complete medium for the indicate times. (top) 10 µg of soluble proteins were immunoprecipitated with saturating amounts of anti–ferritin-H (aFtH). 
The precipitated proteins were separated on a 12% SDS-PAGE. The gels were exposed to autoradiography. The arrows indicate the ferritin subunits. One representative 
of two independent experiments is shown. (bottom) Densitometry quantification of ferritin is shown as percentage of the initial signal.
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neurons expressing the neuronal marker N-CAM using 
fluorescent-specific probes and the In Cell Analyzer system. 
N-CAM detection allows for the identification of all types of 
live neurons. Fluorescence of the ROS-sensor dichlorofluor-
escein (DCF) was collected only from N-CAM–positive 
cells (200 cells per type), and its evaluation indicated higher 
ROS levels in E104X neurons compared with control cells 
(Fig. 4 D). Next, mitochondrial membrane potential was 
evaluated by quantification of tetramethyl rhodamine methyl 
ester (TMRM) signals on N-CAM–positive cells (Fig. 4 F). 
Data collected from 150 cells per type indicated that 
the mitochondrial membrane potential was not affected in 
E104X neurons (Fig. 4 F). In addition, neurons were tested 
for iron deficiency by analyzing TfR1 levels. Cells were stained 
with anti-TfR1 and TuJ1 and the fluorescence emission in 
neurons was quantified by the ImageJ software (Fig. 4 C). 
The plot showed significantly higher TfR1 expression in 
E104X neurons compared with control cells (Fig. 4 E), in-
dicating iron deficiency.
DISCUSSION
In this study, we have identified a new disease entity that 
is hallmarked by a homozygous loss of function mutation in 
the iron storage protein FtL, idiopathic generalized seizures, 
and atypical RLS. Fibroblasts and neurons derived from 
the fibroblasts of this patient show signs of cytosolic iron 
deficiency and oxidative damage, which may explain the clin-
ical findings.
The mutation identified in the FTL gene at nucleotide 
position 310 (G to T) causes a homozygous stop codon. Trun-
cations at this position are incompatible with the folding of 
a functional FtL peptide and thus lead to a loss of FtL func-
tion. As a consequence, only H homopolymer ferritin type is 
formed in all patients’ cells. Thus, for the first time, we were 
able to study human cells completely deficient of the FtL 
subunit. Up until now, human ferritin L subunit deficiency 
was only studied in HeLa cells after RNA interference (Cozzi 
et al., 2004), whereas FtL knockout mice have not been 
reported. Thus, we provide for the first time data on the 
pathophysiological consequences of FtL deficiency in an en-
tire organism.
A G>T nucleotide substitution at position 310 of exon 3 
results in a premature termination codon, which we expected 
to be recognized by mRNA quality control mechanisms and 
degradation by the nonsense-mediated mRNA decay ma-
chinery (Isken and Maquat, 2007). However, FtL mRNA 
levels were similar in the patient’s fibroblasts and controls 
(Fig. 1 D), suggesting that, similar to some mutations in the 
human -globin gene (Romão et al., 2000), this stop codon 
may escape mRNA quality surveillance. Previous mutational 
studies on recombinant FtH (Levi et al., 1989; Yewdall et al., 
1990; Levi et al., 1994; Luscieti et al., 2010) suggested that 
protein truncations (Levi et al., 1989) that occur 5 to aa 155 
in the FtH protein were unable to fold appropriately and 
assemble in a 24-mer shell. Because of the high structural 
homology of the FtH and FtL peptides, the L-variants are 
significant increase in ROS production in E104X fibroblasts 
(Fig. 3 B), whereas control fibroblasts seem to appropriately 
buffer the consequences of H2O2 addition. We further show 
that the levels of carbonylated proteins under basal conditions, 
as assessed by oxyblot, were increased in E104X cells (Fig. 3 C). 
To corroborate these results, we also determined glutathi-
one levels in fibroblasts treated or not with 5 mM of reduc-
ing agent tris(2-carboxyethyl)phosphine (TCEP) for 20 min 
(Schulz et al., 2000). Consistent with an increased oxidative 
status in E104X fibroblasts, an approximately twofold increase 
in the oxidized form of glutathione (GSSG) was observed 
compared with the mean of control cells (Fig. 3 D). More-
over, immunoblotting of ROS scavenger proteins shows a 
reduction of catalase (Fig. 3 E) and superoxide dismutase1 
(SOD1; Fig. 3 F) by 75 and 60%, respectively, in E104X 
cells compared with control subjects. In addition, SOD1 and 
SOD2 activities are reduced (Fig. 3 G), despite unchanged 
SOD2 protein levels (not depicted). In contrast, mRNA ex-
pression for all the three scavenger proteins analyzed is unal-
tered (unpublished data).
H homopolymer ferritin shows a reduced half-life
Both increased oxidative stress (Mehlhase et al., 2005) and 
iron deficiency (De Domenico et al., 2009) promote ferritin 
degradation. To test whether ferritin turnover was altered in 
E104X fibroblasts, we investigated the ferritin degradation 
rate by pulse chase experiments. Cells were metabolically la-
beled with 50 µCi [35S]methionine for 18 h, and ferritin was 
immunoprecipitated at the indicated times applying an anti–
H chain antibody (aFtH). In control cells, the ferritin half-life 
was 18 h as previously reported (Cozzi et al., 2006), whereas 
it was reduced to 5 h in E104X cells (Fig. 3 H).
Neurons derived from patient fibroblasts  
show increased ROS level without alteration  
of the mitochondrial membrane potential
To assess whether increased oxidative stress observed in 
E104X fibroblasts is also preserved in a cellular model more 
appropriate to the investigation of neuronal impairment, we 
took advantage of a recently developed technology, which al-
lows us to directly convert human fibroblasts into neuronal 
cells (Vierbuchen and Wernig, 2011). Patient fibroblasts were 
transduced with a cocktail of lentiviral vectors carrying 
the Mash1, Nurr1, and Lmx1 transcription factors under 
the control of a Tet-inducible promoter (Caiazzo et al., 2011). 
Combined expression of these transcription factors induces 
the formation of dopaminergic neurons (Caiazzo et al., 2011). 
21 d after transduction, the expression of neuronal markers, 
such as neuron-specific class III -tubulin (TuJ1) and tyrosine 
hydroxylase (TH) was detected by immunostaining (Fig. 4 A). 
The efficiency of neuronal transformation evaluated by TuJ1 
positivity was similar in controls and E104X cells ranging be-
tween 5 and 10% (unpublished data). TH positivity was 
detected in 50% of the iNs in control and patient samples 
(Fig. 4 A). We next quantitatively analyzed ROS levels (Fig. 4 B) 
and mitochondrial functionality (Fig. 4 F) in single-derived 
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Figure 4. iNs show increased ROS level 
and TfR1 expression, and unaffected mi-
tochondrial membrane potential. Confocal 
analysis of control and E104X cells (A) 
stained with TuJ1 (top) and TH (middle); 
merge (bottom). (B) Control and E104X live 
cells analyzed by IN-cell analyzer stained 
with the ROS sensible fluorescent probe DCF 
(top) and with the neuronal specific anti– 
N-CAM antibody (middle); merge in the (bot-
tom). (C) Control and E104X fixed cells were 
analyzed for TfR1 signal (top) and with neu-
ronal specific anti-TuJ1 antibody (middle); 
merge in the (bottom). (D) DCF fluorescence 
from N-CAM–positive cells (from B) were 
quantified, and the data are shown in the 
plots (mean ± SEM). *, P ≤ 0.004. Results are 
the mean of three independent experiments 
(total of 200 neurons for each subject).  
(E) TfR1-associated fluorescence from TuJ1-
positive cells (from C) were quantified and 
the data are shown in the plots (mean ± 
SEM). *, P ≤ 0.007. Results are the mean of 
three independent experiments (total of 20 
neurons for each subject). (F) TMRM fluores-
cence signal from the N-CAM–positive cells 
were quantified (total of 150 neurons for 
each subject), and the data are shown in the 
plot. Results are the mean of three indepen-
dent experiments (mean ± SEM).
expected to behave in a similar manner. Indeed our qualita-
tive and quantitative analysis of FtL expression suggests that 
the full ferritin protein cage lacks the FtL subunit in fibro-
blasts derived from the patient. Thus, the disease phenotype 
may result either from a loss of FtL function or a gain of 
function via altered activity of the FtH homopolymer. Im-
portantly, we did not detect an increased amount of FtH ex-
pression, suggesting that a compensatory effect between the 
two genes does not exist, at least in the cell type studied.
The FtL functionality data, obtained by overexpression 
(Cozzi et al., 2000) and RNA interference studies in HeLa 
cells (Cozzi et al., 2004), indicated that alterations of FtL lev-
els do not affect cellular iron homeostasis or the sensitivity to 
oxidative stress. The only effect detected in cells overexpress-
ing FtL was increased cell proliferation that likely resulted 
from iron-independent mechanisms. RNA interference re-
duced FtL expression by 80%, suggesting that 1 or 2 FtL 
ferritin subunits are still incorporated in the heteropolymer. 
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the pathogenesis of Alzheimer’s disease. Correlation of sys-
temic iron deficiency and serum oxidative stress markers are 
also reported in patients with anemia (Rajendiran et al., 2012). 
Our results support the data from previous studies and may 
be explained by the severe reduction of cytosolic scavenger 
proteins, such as catalase and SOD1. Catalase and SOD1 pro-
teins may be destabilized, as mRNAs levels are unchanged. 
Catalase is a heme-containing enzyme and thus iron depri-
vation limits its functionality (Wan et al., 2012; Kurtoglu 
et al., 2003). Likewise, apo-catalase is degraded faster. Moreover, 
the turnover of SOD1 is promoted (Wan et al., 2012; Kurtoglu 
et al., 2003) by increased H2O2 levels as a result of catalase 
reduction (Pigeolet et al., 1990). Furthermore, ferritin itself 
is known to be more quickly degraded by cellular iron de-
privation (De Domenico et al., 2009). Despite the iron re-
leased from damaged ferritin, the LIP remains low. This 
suggests that the kinetics of iron incorporation into the FtH 
homopolymer (Km,Fe, 80 µM; kcat, 201 min1; Sun et al., 1993) 
supersedes the cellular capacity to maintain iron levels. Thus, 
a FtH homopolymer appears to induce cellular iron defi-
ciency, which is sufficient to affect the antioxidant cellular 
defense system and to increase ROS levels. ROS trigger the 
oxidative cascade, inducing accelerated ferritin degradation, 
which promotes the release of iron from its cavity and con-
tributes to the increase of ROS with the creation of a vicious 
detrimental cycle. The presence of the two ferritin subunit 
types thus appears to be crucial to preserve the functionality 
of the molecule, and the precise H/L subunit ratio is vital to 
maintaining iron homeostasis.
Iron is essential in several brain processes, such as neurome-
tabolism, myelination, synthesis, and catabolism of neurotrans-
mitters (Rouault and Cooperman, 2006; Snyder and Connor, 
2009). Iron deficiency results in impaired brain development, as 
well as cognitive, behavioral, and psychomotor impairment to 
name the most worrisome manifestations (Lozoff and Georgieff, 
2006). In addition, iron deficiency causes alopecia in mice (Du 
et al., 2008), whereas in humans a causal link has not been 
proven (Trost et al., 2006; Daniells and Hardy, 2010). Our 
patient shows all these phenotypes, supporting the impor-
tance of iron availability for brain function and hair loss.
There are conflicting reports as to whether iron deficiency 
may be involved in the susceptibility to seizures. Mice main-
tained on an iron deficient diet, with or without addition of lead, 
showed more spontaneous seizures with a shortened latency of 
onset compared with those maintained on a normal iron diet 
(Barzideh et al., 1995), suggesting that iron deficiency improved 
lead toxicity. A recent epidemiological study on a population 
with a high prevalence of iron deficiency concluded that there is 
no association between iron deficiency and acute seizures (Idro 
et al., 2010). However, the meta-analysis of eight case-control 
studies that have examined the relationship between iron defi-
ciency and febrile or acute seizures indicated that iron deficiency 
may be associated with an increased risk of febrile seizures in 
children (Idro et al., 2010; Sherjil et al., 2010).
Idiopathic generalized epilepsy (IGE) is a group of epi-
lepsy that has very distinct features. It is also called “primary” 
Moreover, in vitro–reconstituted H/L heteropolymers indi-
cated that the presence of even a small proportion (2–4 chains 
per shell) of FtL subunits is sufficient to confer maximum 
functional properties to the ferritin molecule (Santambrogio 
et al., 1993). The data obtained in this study analyzing cells 
completely deficient for FtL demonstrate that we must revise 
our concept of the void effect of FtL deficiency on cellular 
iron metabolism. We show that the absence of FtL triggers 
cellular iron deficiency due to the higher iron avidity of the 
H homopolymer compared with the ferritin heteropolymer 
expressed in the control cells (Fig. 2 B). This finding was fur-
ther corroborated by demonstrating a decrease of the LIP and 
an increase of IRP activity in patient’s fibroblasts. As a conse-
quence, TfR1 levels are elevated, which will pilot more iron 
into the cell. However, despite this compensatory response, 
the LIP remains low. This finding indicates that the iron in-
corporation capacity of FtH overcomes the ability of the cell 
to replenish the LIP with iron.
Iron insufficiency was recently described as a molecular 
mechanism for motor neuron degeneration in IRP2-null 
mice (Rouault and Cooperman, 2006). Impaired control of 
iron metabolism by IRP2 deficiency causes cellular iron star-
vation induced by decreased levels of the iron importer TfR1 
and the overexpression of both ferritin subunits (Jeong et al., 
2011). In this case, the iron supply to mitochondria was af-
fected with the consequent impairment of organelle func-
tionality and motor neuron degeneration (Jeong et al., 2011). 
In our patient who has a FtL–null allele, only SOD2 activity 
appears disturbed, whereas ATP production and mitochon-
drial membrane potential are not affected, at least in fibro-
blasts and in induced neuronal cells (Fig. 4 F). We speculate 
that the level of iron deficiency in this patient is restricted to 
the cytosol and that it is not severe enough to affect the mito-
chondrial compartment. This difference may be explained by 
the lower iron requirement of fibroblasts or iNs compared 
with motor neurons. However, this mitochondrial functional 
preservation sustains the hypothesis that iron supplementa-
tion to mitochondria is a priority for cells.
Furthermore, our data indicate that the patient’s fibro-
blasts show reduced resistance to H2O2 treatment associated 
with increased ROS production compared with control cells. 
Indeed, the oxidative status in patient’s cells is altered also 
under basal conditions, as indicated by the increased amount 
of carbonylated protein and oxidized glutathione. Enhanced 
ROS levels are also detected in neurons under basal condi-
tions, confirming that they are more sensitive to iron varia-
tion compared with other cell types. Indeed, we also detected 
enhanced TfR1 levels in neurons, suggesting iron deficiency. 
Oxidative damage is commonly associated with iron excess 
(Arosio and Levi, 2010); however, both in vitro and in vivo 
evidence suggests, that it can be also induced by iron defi-
ciency. Wan et al. (2012) found that overexpression of wild-
type human amyloid- protein precursor (APP) decreased 
iron levels and increased oxidative stress in neuroblastoma 
SH-SY5Y cells because of a reduction of catalase activity, sug-
gesting that iron deficiency in APP cells may contribute to 
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the age of 7 yr. A treatment with valproic acid was stopped at the age of 
22 yr because of weight gain, progressive hair loss, and no reoccurrence of 
epilepsy for more than 5 yr. After that, the patient remained without relapse. 
Both parents of the patient originate from the same region in Calabria and 
show no relevant medical history; in particular no neurological disorders 
were present. The patient is not retarded in growth, but shows mild neuro-
psychological impairment with a reduced intelligence quotient. Therefore, 
she was not able to finish her pursuit of an assistant nursing job and is receiv-
ing disability pension. Due to important progressive hair loss despite the ces-
sation of valproic acid, the general practitioner (GP) performed a check-up. 
Serum ferritin was below the detection limit (<1 µg/liter) and treatment 
with 1,400 mg intravenous iron was prescribed by the GP. Interestingly, 
the ferritin remained unchanged (<1 µg/liter). Beside the remarkable hair 
loss, physical examination of the patient was unremarkable. Because blood 
values including hemoglobin concentration, mean corpuscular volume (MCV), 
mean corpuscular hemoglobin concentration (MCHC), total RBCs, and 
haptoglobin were normal, we concluded that erythropoiesis was not im-
paired as a consequence of functional iron deficiency. Furthermore, serum 
iron levels, transferrin, and transferrin-saturation were within the normal 
range, implying that systemic iron homeostasis was not affected (Table 2). 
The reason for the undetectable ferritin was completely unclear. We ex-
cluded an antibody-mediated phenomenon by performing a 1:1 mixing test 
with a normal sample and found no increased reduction of ferritin. Several 
other commercially available ferritin tests were applied, but the results ob-
tained were equal. To further exclude a transmembrane transport defect, we 
lysed all blood cells and measured ferritin levels, which were still undetect-
able. Because of neurological symptoms during childhood and a suspected 
alteration of ferritin itself, we suggested the diagnosis of a disorder close to 
neuroferritinopathy even though in this group of patients ferritin is still de-
tectable in serum. However, in repeated MRI no iron deposition in basal 
ganglia could be found and sequencing of exon 4 of the FTL1 gene has not 
identified neuroferritinopathy-associated mutations. An additional neuro-
logical examination, including polysomnography, found a restless limb syn-
drome beside the known idiopathic generalized epilepsy during childhood. 
To get additional insight into iron deposition, we performed a T2* MRI of 
generalized epilepsy. Patients with IGE have one or several of 
three types of (primary generalized) seizures: myoclonic, ab-
sence, and generalized tonic-clonic seizures. Up to now, to the 
best of our knowledge there are no data supporting a higher 
incidence of IGE in patients with iron deficiency.
On the contrary, the correlation between RLS and iron 
deficiency is well documented (Connor et al., 2011). RLS is 
defined as sensorymotor disorder, the key feature of which is an 
urge to move the legs usually accompanied by abnormal sensa-
tions in their legs, particularly during rest (Allen and Earley, 
2007). Several clinical and laboratory studies have demonstrated 
a negative correlation between body iron stores and severity of 
symptoms (Connor, 2008). Magnetic resonance imaging (MRI) 
and histochemical studies documented brain iron deficiency 
in selected brain regions of these patients (Earley et al., 2006; 
Godau et al., 2008; Snyder et al., 2009). These data stimulated 
several clinical trials based on iron supplementation in these 
patients that seems to be efficient in reducing symptoms of 
RLS (Earley et al., 2009; Cho et al., 2013).
The extended studies in our patient support a causative 
correlation of diminished cytoplasmic iron availability and the 
development of epilepsy and RLS. Thus, intracellular iron defi-
ciency, induced by the absence of FtL chain, appears a common 
cause that may trigger different neurological phenotypes.
MATERIALS AND METHODS
Case. A 23-yr-old female patient was referred to the Department of He-
matology of the University Hospital Zürich for further evaluation of iron 
deficiency. The patient suffered from idiopathic generalized seizures since 
Table 2. Hematological parameters of the patient
Parameter Value Reference value
Hemoglobin 140 g/liter 117–153 g/liter
Hematocrit 0.425 liter/liter 0.35–0.46 liter/l
Erythrocytes 4.68 T/liter 3.9–5.2 T/l
MCV 90.8 fl 80–100 fl
MCH 29.9 pg 26–34 pg
MCHC 329 g/liter 310–360 g/liter
Reticulocytes (relative) 1.8% 0.4–2.5%
Reticulocytes (absolute) 83 G/liter 27–132 G/l
Leukocytes 9.15 G/liter 3.0–9.6 G/l
Neutrophils 5.44 G/liter 1.4–8.00 G/l
Monocytes 0.64 G/liter 0.16–0.95 G/l
Eosinophils 0.05 G/liter 0.00–0.70 G/l
Basophils 0.00 G/liter 0.00–0.15 G/l
Lymphocytes 3.02 G/liter 1.50–4.00 G/l
Iron 15.0 mol/liter 7.0–26.0 mol/l
Ferritin < 1.0 µg /litera 10–150 µg /l
Transferrin 28.0 mol/liter 25–50 mol/l
Transferrin saturation 27.0% 15–50%
Hepcidin 3.1 nmol/liter 0.5–6.6 nmol/l
Hematological values were determined by clinical methods with the exception of serum hepcidin, which was measured using the Hepcidin 25 bioactive ELISA (DGR 
International) following the manufacturer’s instructions.
aResult is outside the reference value.
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and incubated for 1 h at 37°C with anti–rabbit or anti–mouse secondary 
antibody Alexa Fluor 488 or Alexa Fluor 594 (Molecular Probes; 1:500 in 
PBS, 1% BSA).
RNA extraction and real-time PCR. Total RNA was isolated from fi-
broblasts cultured in T75 flasks (80% confluence) using the RNeasy kit 
(QIAGEN) protocol for adherent cells. RNA quantity was measured using a 
NanoDrop (NanoDrop Technologies), and 1 µg of each sample was incu-
bated with 1 U DNaseI (Invitrogen) for 15 min at room temperature. After 
DNase inactivation at 65°C for 10 min, RNA was used as a template to gen-
erate cDNA by a High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems). For negative controls, the reverse transcription was omitted. 
Reverse transcription products were used in real time PCR to evaluate the 
expression level of FtL (primers: 5-ACCTCTCTCTGGGCTTCTAT-3 
and 5-AGCTGGCTTCTTGATGTCCT-3), FtH (primers: 5-CCATGT-
CTTACTACTTTGACC-3 and 5-GTCTGGTTTCTTGATATCCTG-3; 
both synthetized by Primm), catalase (primer: Hs_CAT_1_SG), SOD1 
(primer: Hs_SOD1_1_SG; all from QIAGEN) relative to GAPDH with the 
SYBR Green PCR Master Mix (Applied Biosystems) system.
Cellular 55Fe incorporation. Cells (2 × 105) were incubated for 18 h with 
2 µCi/ml 55Fe-ferric ammonium citrate (FAC; Perkin Elmer and Analytical 
Sciences; ratio 1:2) and 200 µM ascorbic acid (Sigma-Aldrich) in DMEM 
0.5% FBS, 0.5% BSA. Cells were washed and lysed in 0.3 ml of lysis buffer 
(10 mM Hepes, pH 7.4, 137 mM NaCl, 2 mM EDTA, 10% glycerol, and 2% 
chaps; all from Sigma-Aldrich), and 10 µl of the soluble fraction was mixed 
with 0.3 ml of Ultima Gold (Packard) and counted for 3 min in a scintilla-
tor counter (Packard). 10 µg of soluble fraction was analyzed also on 7% 
nondenaturing PAGE. Gel was fixed and dried and exposed to autoradiogra-
phy. The intensity of the ferritin bands was quantified by densitometry.
LIP. Cells (4 × 104) were incubated with 0.250 µM calcein-AM (Invitrogen) 
for 15 min at 37°C in bicarbonate-free medium containing 1 mg/ml BSA 
and 20 mM Hepes, pH 7.3. After washing with PBS, HBS (154 mM NaCl 
and 20 mM Hepes, pH 7.2) was added to the cells, and the fluorescence was 
monitored at an excitation of 485 nm and an emission of 535 nm on Victor 
3 plate reader (Perkin Elmer). The quenching of calcein by intracellular iron 
was revealed by the addition of 0.2 mM deferiprone.
EMSA. To perform the EMSA, cell extracts (2 µg of total soluble proteins) 
were incubated with a molar excess of 32P-labeled IRE probe (100,000 cpm) 
in the presence or absence of 2% -mercaptoethanol. The IRE probe was 
generated by in vitro transcription of the plasmid pSPT-fer. The plasmid was 
linearized with BamHI and transcribed by T7 RNA polymerase in the pres-
ence of 80 µCi 32P UTP (ICN; Campanella et al., 2009).
Ferritin quantification and immunoblotting. Ferritin levels were de-
termined by ELISA using the monoclonal antibodies L03 (specific for the 
FtL) and rH02 (specific for the FtH) calibrated on the corresponding recom-
binant homopolymer (Cozzi et al., 1989). Protein concentration was evalu-
ated by the bicinchoninic acid (BCA) method (Thermo Fisher Scientific) 
calibrated on BSA. 20 µg of soluble proteins were separated by sodium do-
decyl sulfate–PAGE (SDS-PAGE), and immunoblotting was performed using 
specific antibodies for Catalase (EMD Millipore), SOD1 (Santa Cruz Bio-
technology, Inc.), SOD2 (Santa Cruz Biotechnology, Inc.), TfR1 (Zymed), 
and -actin (Sigma-Aldrich), followed by peroxidase-labeled secondary anti-
bodies (Sigma-Aldrich). Band intensity was revealed by enhanced chemilu-
minescence (ECL; GE Healthcare).
Cell viability assay. 104 cells were grown in complete medium for 18 h at 
37°C, washed with PBS, incubated for 1 h in serum-free medium, and then 
added to 0.6 mM H2O2 for 2 h. The plates were washed with PBS and cellular 
viability was measured by incubation with 10 µl MTT solution (5 mg/ml in 
phosphate-buffered saline) for 2 h at 37°C. Color absorbance was read at 570 nm, 
following manufacturer’s instruction (Sigma-Aldrich; Cozzi et al., 2000).
the liver, which revealed normal iron stores. Because physiologically only 
FtL can be found in the serum we suspected a previously undescribed muta-
tion in the FtL gene of the patient.
PCR amplification and sequencing of patient DNA. Genomic DNA 
was extracted from peripheral blood using the QIAamp DNA Blood Mini 
kit (QIAGEN) according to manufacturer’s instructions. PCR amplification 
of FtL was performed with 70 ng of genomic DNA (for primers see below) 
with the following conditions: denaturation at 95°C, annealing at 58°C, and 
extension at 72°C, step 1 and 2 for 30 s, step 3 for 45 s, and for 38 cycles. The 
resulting amplification products were verified on a 1.5% agarose gel. To re-
move excess dNTPs and unincorporated primers, 40 µl of PCR product was 
cleaned by application of the NucleoSpin Gel and PCR Clean-up kit (Ma-
chery-Nagel) according to manufacturer’s instructions. The purified PCR 
products were sequenced using the conventional Sanger method by GATC 
BIOTECH. Sequencing results were analyzed manually using the Chromas 
software (Technelysium Pty Ltd). F1, 5-GGGCTGAGACTCCTATGTG-3; 
R1, 5-GACTCCGCCCTCTGTTTACC-3; F2, 5-AGCTCCCAG-
ATTCGTCAGAA-3; R2, 5-CGGTTAAGAGGGCTCACAAG-3; F3, 
5-GCTACGAGCGTCTCCTGAAG-3; R3, 5-CCATCTGGGAGGGA-
CAGTTA-3 (F1+R1→559bp, F2+R2→535bp, F3+R3→1226bp).
Cell culture. We analyzed primary skin fibroblasts from three unaffected 
subjects (Control: 1, 2 and 3; selected from the Movement Disorders BioBank 
available at the Neurogenetics Unit of the Neurological Institute “Carlo 
Besta” (INCB, Milan, Italy) and purchased by ATCC, and our patient who is 
homozygous for the nucleotide substitution G310T in exon 3 of the FtL 
gene (E104X). A primary fibroblast cell line was generated from skin biopsy. 
Fibroblasts were grown in DMEM (Invitrogen) supplemented with 10% FBS 
(Invitrogen), 100 mg/ml streptomycin, 100 U penicillin, and 2 mM L-glutamine 
(Sigma-Aldrich).
Fibroblast transduction. 50 multiplicity of infection of VS-pseudotyped 
lentiviral vector pGK-GFP-Lwt (gift from L. Politi, San Raffaele Scientific 
Institute, Milan, Italy) was used to transduce 2 × 105 of control (CTR1) and 
E104X cells. After 48 h, GFP cells were visualized using a fluorescence mi-
croscope to test transduction efficiency. The cells were tested for ferritin ex-
pression after growth for up to 10 d in DMEM supplemented with 10% FBS, 
100 µg/ml streptomycin, 100 U penicillin, and 2 mM L-glutamine; ferritin 
levels was determined by specific ELISA (Cozzi et al., 1989).
Generation of iNs from human fibroblasts by direct reprogram-
ming. Human fibroblasts from our patient (E104X) and controls (adult fi-
broblasts from ATCC) were grown in medium for fibroblasts (DMEM, FBS, 
nonessential amino acids, sodium pyruvate, and penicillin/streptomycin) 
plated onto Matrigel-coated 24-well plates (5 × 104 cells/well). For immuno-
histochemical analysis, some of these cells were plated onto Matrigel-coated 
glass coverslips. The second day, fibroblasts were infected by lentivirus in 
which cDNAs for transcription factors (Mash1, Nurr1, and Lmx1a) were 
cloned (Caiazzo et al., 2011) under the control of a tetracycline-responsive 
promoter. 16–20 h after infection, cells were switched into fresh fibroblast 
medium containing doxycycline (2 mg/ml) and after further 48 h, the me-
dium was replaced with neuronal inducing medium (DMEM F12, 25 µg/ml 
insulin, 50 mg/ml transferrin, 30 nM sodium selenite, 20 nM progesterone, 
and 100 nM putrescine and penicillin/streptomycin) containing doxycycline 
(all from Sigma). The medium was changed every 2–3 d for further 20 d.
Fluorescence staining. 20 d after viral infection those cells that underwent 
direct reprogramming were fixed in 4% Paraformaldehyde in PBS for 20 min 
at room temperature, permeabilized for 30 min in 0,1% Triton X 100, 10% 
normal goat serum PBS. Then the cells were incubated 1 h at 37°C with 
mouse anti Beta III tubulin (TuJ1; 1:500; Covance), or with rabbit anti-tyrosine 
hydroxylase (TH; 1:200; Covance), or with mouse anti-TfR1 (1:1,000; Zymed) 
antibodies in PBS with 1% BSA. The cells were washed three times with PBS 
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between controls and patients were determined by the Student’s t test, which 
was considered significant when P ≤ 0.05.
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Reactive oxygen species (ROS) detection. Fibroblasts (104) were incu-
bated with 30 µM DHR-123 (Molecular Probes) for 15 min at 37°C, and 
then washed with PBS and maintained in HBSS supplemented with 1 mM 
glucose. Fluorescence was determined using the Victor3 Multilabel Counter 
(PerkinElmer) at 485 and 535 nm for excitation and emission, respectively. 
Cells were incubated in HBSS for 30 min at 37°C with different amounts of 
H2O2 and, finally, fluorescence was determined as above.
iNs generated from fibroblasts were incubated with Alexa Fluor 647 
mouse anti–human CD 56 (N-CAM; BD; dil. 1/40) for 1 h, with 20 µM 
2,7-DCF (CM-H2CFDA; Molecular Probes) for 15 min, and with 2 µg/ml 
of Hoechst 33342 for 3 min. All of these incubations were performed at 
37°C. Cells were washed and analyzed by IN-Cell Analyzer 1000 system (GE 
Healthcare). Fluorescence of DCF from N-CAM–positive cells was collected 
to compare the relative ROS content.
Mitochondrial membrane potential assay. The same fluorescent detec-
tion procedure described above was performed to determine mitochondrial 
membrane potential using Alexa Fluor 488 mouse anti–human N-CAM 
(BD; dil.1/40) and 20 nM TMRM treatment for 15 min.
Glutathione assay. 104 cells were plated in complete medium and treated 
with 5 mM of TCEP (tris[2-carboxyethyl]phosphine) for 20 min at room 
temperature. GSH-Glo Reagent and Luciferin Detection Reagent, accord-
ing to Promega protocol kit, were added and the plates were incubated at 
room temperature for 30 and 15 min, respectively. Finally, the luminescence 
was read on Victor 3 reader (Perkin Elmer).
Oxidized protein detection. Oxidized proteins were detected using the 
Oxyblot Protein Oxidation Detection kit (EMD Millipore) following man-
ufacturer’s instructions. In brief, the soluble protein extracts were derivatized 
to 2,4-dinitrophenylhydrazone (DNP), and 1 µg was loaded on 12% SDS-PAGE, 
blotted, and incubated with an anti-DNP antibody. The bound activity was 
revealed by ECL advance (GE Healthcare).
SOD activity measurement. Total cell homogenates (15 µg) were ana-
lyzed for SOD activity after separation on a 12% nondenaturing PAGE with 
nitro blue tetrazolium staining (White et al., 1993). In brief, the gels were 
stained with 0.025% nitro blue tetrazolium (Sigma-Aldrich) and 0.01% 
riboflavin (Sigma-Aldrich) dissolved in H2O for 20 min in the dark. 1% 
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Metabolic labeling and immunoprecipitation. Cells were metabolically 
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[35S]cysteine (ICN) was added and the cells were grown for other 18 h. The 
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again with an anti–FtH antibody and analyzed on 12% SDS-PAGE. The gels 
were treated with autoradiography image enhancer (Amplify), dried, and ex-
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intensity of ferritin subunit bands was quantified by densitometry.
Statistical analyses. The data, except where otherwise indicated, are re-
ported as the mean ± SD values or as a representative of at least three inde-
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